Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin-

Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic Body Radiation

Therapy (SBRT)

Fiori Alite, M. Surucu, I. Mescioglu, M. Harkenrider

Loyola University Medical Center, Maywood, IL

IntroductionIntroduction

• Angiotensin Converting Enzymes have demonstrated efficacy in preclinical models of ameliorating lung radiation toxicity

• 4 Retrospective reviews have demonstrated conflicting results in terms of documenting improvement of symptomatic radiation pneumonitis

• RTOG 0123 was initiated to test efficacy of the ACEi captopril to decrease rates of symptomatic pneumonitis in patients treated with radiation for locally advanced non-small cell and small cell lung carcinoma

• To our knowledge, effect of concurrent ACEi use in patients treated with lung SBRT has not been tested

• The objective of this study was to evaluate retrospectively the role of concurrent incidental use of ACE inhibitors in ameliorating development of symptomatic acute lung toxicity in the setting of thoracic SBRT.

Materials and MethodsMaterials and Methods

• A retrospective review of patients treated with thoracic SBRT analyzing rates of incidental concurrent use of ACEi and development of symptomatic pneumonitis was performed.

• We analyzed 193 patients treated with Linac-based SBRT with for primary, recurrent and metastatic lung tumors. Patients were treated with doses of 40-60Gy in 3-5 fractions from 2006 to 2013.

• These plans were evaluated to meet RTOG 0236 criteria for dose coverage and lung tolerance.

• We recorded symptomatic pneumonitis up to 6 months post treatment based on Common Terminology Criteria for Adverse Events Version 4.0.

• Pre and post treatment medication profiles were reviewed to document use of ACE inhibitors, angiotensin receptor blockers, bronchodilators, ASA, PDE5 inhibitors, nitrates and endothelin receptor antagonists. A decision tree analysis was performed to investigate the risk factors for development of symptomatic pneumonitis.

• Patient age, sex, KPS, clinical stage, tumor location, prescription dose, and concurrent use of 7 different bronchoactive medications were used to train this decision tree.

ResultsResults

• The majority (85%) of patients were treated with 50Gy in 5 fractions, and 8% of patients with 60Gy in 5 fraction.

• Twenty three patients experienced Grade 2 or higher pneumonitis, an absolute rate of 11.9%.

• Forty-eight patients (24.9%) were found to be on ACEi during delivery of SBRT.

• Only one patient on a concurrent ACEi experienced symptomatic pneumonitis.

• The rate of Grade 2 or higher pneumonitis was significantly lower in patients prescribed an ACEi vs. patients not on an ACEi (2% vs. 15%, χ2

test p = 0.01).

• Additionally, in a decision tree analysis accounting for the clinical/patient characteristics and medication profiles we can predict with 92% accuracy that patients on an ACEi will not experience symptomatic pneumonitis.

Patient CharacteristicsPatient Characteristics

No 47/1

Decision Tree AnalysisDecision Tree Analysis

• ACEi appear to have efficacy in diminishing rates of symptomatic pneumonitis in the setting of lung stereotactic body radiation therapy which was validated in a decision tree statistical analysis.

• With the advent of increased lung cancer screening as well as expanding clinical practice of treating lung oligometastases, identifying toxicity modifiers in this population with often compromised lung function is important.

• This is of particular concern in patients that are receiving several courses of radiation to the chest, or patients treated to multiple sites and overall greater lung volume.

• Prospective analysis is needed to confirm these findings.

ConclusionsConclusions

ReferencesReferences1. Rutter CE, Corso CD, Park HS, et al. Increase in the use of lung stereotactic body radiotherapy

without a preceding biopsy in the United States. Lung Cancer. 2014.

2. Marks LB, Yu X, Vujaskovic Z, Small W, Folz R, Anscher MS. Radiation-induced lung injury.

Semin Radiat Oncol. 2003;13(3):333-345.

3. Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR. Radiation-induced lung injury. Assessment,

management, and prevention. Oncology (Williston Park). 2008;22(1):37-47; discussion 52-33.

4. Hill RP. Radiation effects on the respiratory system. BJR Suppl. 2005;27:75-81.

5. Ward WF, Molteni A, Ts'ao CH. Radiation-induced endothelial dysfunction and fibrosis in rat

lung: modification by the angiotensin converting enzyme inhibitor CL242817. Radiat Res.

1989;117(2):342-350.

6. Molthen RC, Wu Q, Fish BL, Moulder JE, Jacobs ER, Medhora MM. Mitigation of radiation

induced pulmonary vascular injury by delayed treatment with captopril. Respirology.

2012;17(8):1261-1268.

7. Ghosh SN, Zhang R, Fish BL, et al. Renin-Angiotensin system suppression mitigates

experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2009;75(5):1528-1536.

8. Kma L, Gao F, Fish BL, Moulder JE, Jacobs ER, Medhora M. Angiotensin converting enzyme

inhibitors mitigate collagen synthesis induced by a single dose of radiation to the whole thorax. J

Radiat Res. 2012;53(1):10-17.

9. Mahmood J, Jelveh S, Zaidi A, Doctrow SR, Medhora M, Hill RP. Targeting the Renin-

Angiotensin system combined with an antioxidant is highly effective in mitigating radiation-

induced lung damage. Int J Radiat Oncol Biol Phys. 2014;89(4):722-728.

10. Wang LW, Fu XL, Clough R, et al. Can angiotensin-converting enzyme inhibitors protect against

symptomatic radiation pneumonitis? Radiat Res. 2000;153(4):405-410.

11. Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. Decreased risk of radiation pneumonitis with

incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation

therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):238-243.

12. Wang H, Liao Z, Zhuang Y, et al. Do angiotensin-converting enzyme inhibitors reduce the risk of

symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive

radiation therapy? Analysis of a single-institution database. Int J Radiat Oncol Biol Phys.

2013;87(5):1071-1077.

13. Jenkins P, Watts J. An improved model for predicting radiation pneumonitis incorporating

clinical and dosimetric variables. Int J Radiat Oncol Biol Phys. 2011;80(4):1023-1029.